Subjects n | 58 |
Height cm | 166.2±7.0 |
Weight kg | 67.7±13.6 |
Sex | |
Male | 6 (10.3) |
Female | 52 (89.7) |
Time between exercise echo studies years | 3.9±0.9 |
Time between RHC studies years | 2.4±1.3 |
Age at diagnosis years | 46.7±11.3 |
Age at first non-Raynaud symptom years | 46.9±11.7 |
Age years | |
Baseline | 51.3±11.5 |
Follow-up | 55.3±11.6 |
Time since diagnosis years | |
Baseline | 3.0 (1.1–6.9) |
Follow-up | 6.7 (5.2–11.5) |
Patients on bosentan therapy | |
Baseline | 4 (6.9) |
Follow-up | 16 (27.6) |
Patients on immunosuppressive therapy | |
Baseline | 17 (29.3) |
Follow-up | 18 (31.0) |
Uric acid mg·dL−1 | |
Baseline | 4.5 (3.9–5.2) |
Follow-up | 4.7 (4.0–5.6) |
Patients with ACA positivity | |
Baseline | 30 (51.7) |
Follow-up | 33 (56.9) |
Patients with telangiectasis | |
Baseline | 26 (44.8) |
Follow-up | 29 (50.0) |
Rodnan skin thickness score | |
Baseline | 7.3±8.1 |
Follow-up | 6.7±6.7 |